<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04100473</url>
  </required_header>
  <id_info>
    <org_study_id>Samba-04</org_study_id>
    <nct_id>NCT04100473</nct_id>
  </id_info>
  <brief_title>Dose Response of Dance 501 in Subjects With Type 2 Diabetes Mellitus</brief_title>
  <acronym>T2DM</acronym>
  <official_title>A Randomized, Open-Label, 6-Period Cross-Over Study to Investigate the Dose Response of Dance 501 (Human Insulin Inhalation Solution and Inhaler) in Subjects With Type 2 Diabetes Mellitus (T2DM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dance Biopharm Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Profil Institut für Stoffwechselforschung GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Dance Biopharm Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a randomized, open-label, active-controlled, 6-period crossover study. Target
      population will be subjects with Type 2 Diabetes Mellitus (T2DM)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assess the dose-response and dose-exposure of Dance 501 (Human Insulin Inhalation
      Solution) administered with the Dance 501 Inhaler.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 23, 2018</start_date>
  <completion_date type="Actual">August 1, 2019</completion_date>
  <primary_completion_date type="Actual">August 11, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Randomized, Open-Label, Cross-Over design</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Pharmacokinetic Endpoint - PK 1</measure>
    <time_frame>0 - 10 hours</time_frame>
    <description>Area under the human insulin and insulin lispro concentrations time curves</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Pharmacokinetic Endpoint - PK 2</measure>
    <time_frame>0 - 10 hours</time_frame>
    <description>Maximum observed concentration of human insulin and insulin lispro</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Pharmacodynamic Endpoint - PD 1</measure>
    <time_frame>0 - 10 hours</time_frame>
    <description>Area under the glucose infusion rate time curve</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Pharmacodynamic Endpoint - PD 2</measure>
    <time_frame>0 - 10 hours</time_frame>
    <description>Maximum observed glucose infusion rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Pharmacokinetic Endpoint - PK 1</measure>
    <time_frame>0 - 1 hour, 0 - 2 hours, 0 - 8 hours</time_frame>
    <description>Area under the insulin time curves at different intervals</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Pharmacokinetic Endpoint - PK 2</measure>
    <time_frame>0 - 10 hours</time_frame>
    <description>Time to maximum insulin concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Pharmacokinetic Endpoint - PK 3</measure>
    <time_frame>0 - 10 hours</time_frame>
    <description>Relative Efficiency of dose corrected ratio of AUC ins for INH and s.c. lispro</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Pharmacokinetic Endpoint - PK 4</measure>
    <time_frame>0 - 10 hours</time_frame>
    <description>Onset of appearance (time from trial product administration until the serum insulin concentrations are &gt; LLOQ.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Pharmacokinetic Endpoint - PK 5</measure>
    <time_frame>0 - 10 hours</time_frame>
    <description>Mean residence time of insulin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Pharmacodynamic Endpoint - PD 1</measure>
    <time_frame>0 - 1 hour, 0 - 2 hours, 0 - 8 hours</time_frame>
    <description>AUC for GIR at different time intervals</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Pharmacodynamic Endpoint - PD2</measure>
    <time_frame>0 - 10 hours</time_frame>
    <description>Time to maximum glucose infusion rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Pharmacodynamic Endpoint - PD3</measure>
    <time_frame>0 - 10 hours</time_frame>
    <description>Relative biopotency of dose corrected ratio of AUC GIR for INH and s.c. lispro</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Dance 501</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dance 501(Human Insulin Inhalation Solution and Inhaler) will be administered using the Dance 501 Inhaler.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin Lispro</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Insulin Lispro (Humalog®) will be administered by subcutaneous injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled Human Insulin</intervention_name>
    <description>Dance 501 administered using the Dance 501 Inhaler</description>
    <arm_group_label>Dance 501</arm_group_label>
    <other_name>Dance 501</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Lispro (Humalog U-100)</intervention_name>
    <description>Lispro</description>
    <arm_group_label>Insulin Lispro</arm_group_label>
    <other_name>Insulin Lispro (Humalog U-100) will be administered by subcutaneous injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects diagnosed with T2DM.

          -  BMI between 25.0 and 40.0 kg/m2.

          -  Treated with metformin and/or at least 1 daily injection of insulin for at least 6
             months.

          -  Non-smoker for at least 5 years.

          -  Forced vital capacity and forced expiratory volume in one second is at least 75%
             normal.

        Exclusion Criteria:

          -  Any condition affecting pulmonary drug absorption.

          -  History or presence of cancer except basal cell skin cancer or squamous cell skin
             cancer.

          -  Serious systemic infectious disease during four weeks prior to dosing.

          -  Clinically significant abnormal lab values.

          -  Proliferative retinopathy and/or severe neuropathy.

          -  Recurrent severe hypoglycemia.

          -  Current treatment with oral anti-diabetic drugs except metformin, glucagon-like
             peptide receptor agonists.

          -  Current treatment with MAO inhibitors.

          -  Unstable Thyroid hormones for at least 3 months.

          -  Insufficient glycemic control with significant fluctuations of blood glucose.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oliver Klein</last_name>
    <role>Principal Investigator</role>
    <affiliation>Profil Institut fur Stoffwechselforschung GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Profil Mainz</name>
      <address>
        <city>Mainz</city>
        <state>Malakoff-Passage</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>February 25, 2019</study_first_submitted>
  <study_first_submitted_qc>September 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2019</study_first_posted>
  <last_update_submitted>September 20, 2019</last_update_submitted>
  <last_update_submitted_qc>September 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Inhaled Insulin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin Lispro</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

